In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Actavis becomes white knight for Allergan; buys firm for $65bn

Executive Summary

After battling Valeant Pharmaceuticals International Inc. for nearly seven months, Allergan Inc. (specialty pharmaceuticals and aesthetic devices) found another buyer willing to pay more: Actavis PLC will spend $65 billion, or $219.54 per share ($129.22 in cash and 0.3683 in Actavis shares; a 75% premium to Allergan’s ten-day average prior to the initial Valeant announcement). Valeant stated it is reviewing the Allergan/Actavis agreement to determine its next course of action, but cannot justify paying more than $219 per share.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash for Equity
    • Payment Includes Stock

Related Companies